Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/7827
Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies
Int J Mol Sci. 2019;20(11). pii: E2832.
Ultra-deep next-generation sequencing has emerged in recent years as an important diagnostic tool for the detection and follow-up of tumor burden in most of the known hematopoietic malignancies. Meticulous and high-throughput methods for the lowest possible quantified disease are needed to address the deficiencies of more classical techniques. Precision-based approaches will allow us to correctly stratify each patient based on the minimal residual disease (MRD) after a treatment cycle. In this review, we consider the most prominent ways to approach next-generation sequencing methodologies to follow-up MRD in hematological neoplasms.
clonal evolution | hematological neoplasms | high-throughput sequencing | minimal residual disease | next-generation sequencing
Files in this item
- MinimalResidualDiseaseMonitori ...